Sep 30, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Sep 25, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Sep 24, 2025 • Benzinga
NEUTRAL
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ( ACP-101 ) in patients with hyperphagia in Prader-Willi syndrome ( PWS ) .
Sep 17, 2025 • Benzinga
SOMEWHAT-BULLISH
ACADIA Pharmaceuticals EVP Trades $82K In Company Stock - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Mark Schneyer, EVP at ACADIA Pharmaceuticals ACAD, reported an insider sell on September 16, according to a new SEC filing. What Happened: Schneyer's decision to sell 3,498 shares of ACADIA Pharmaceuticals was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday.
Aug 29, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Aug 27, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...